Market Research Logo

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline landscape.

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). In RRMS, there are clear episodes of inflammatory activity (relapses). During a period of acute inflammation, old symptoms may worsen and new symptoms may appear. A relapse is when active inflammation, and the resulting symptoms, last more than 24 hours. Symptoms include tingling or numbness, double vision, fatigue, urinary urgency and weakness. Treatment includes corticosteroids and immunoglobulin therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 18, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Relapsing Remitting Multiple Sclerosis (RRMS).

Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Relapsing Remitting Multiple Sclerosis (RRMS) Overview
Therapeutics Development
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes
Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment
Drug Profiles
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2016
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AB Science SA, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Alkermes Plc, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen Inc, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Coherus BioSciences, Inc., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GeNeuro SA, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by LFB S.A., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H2 2016
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2016
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report